Viatris’Mylan Pharmaceuticals Inc. is to set for another chance to avoid a judgment of infringement that is currently blocking a path to market for the firm’s proposed generic version of AstraZeneca’s blockbuster Symbicort (budesonide/formoterol fumarate dihydrate) pressurized metered dose inhaler.
In a 2-1 split decision, the US Court of Appeals for the Federal Circuit has vacated Viatris’ earlier stipulated judgment of infringement entered at the district court level after ruling that